Online inquiry

IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12083MR)

This product GTTS-WQ12083MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12083MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2068MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ10180MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ12643MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ4037MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ14011MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ1459MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ5035MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ3975MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW